ReviewAnnals of surgical oncology2024
Histology-Tailored Approach to Soft Tissue Sarcoma.
Review in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Soft Tissue Reporting and Data System (Soft Tissue-RADS): preliminary validation among fellowship-trained musculoskeletal radiologists.European radiology · 2026Article
- Robotic-assisted compartmental dissection for retroperitoneal sarcoma: a feasibility study on cadavers with the da Vinci Xi system.Journal of robotic surgery · 2026Article
- Surgery confers survival benefit in De Novo metastatic soft tissue sarcoma patients with low Ki67 or low total lesion glycolysis: a combined PET/CT and clinicopathological analysis.European radiology · 2026Article
- Pelvic Retroperitoneal Solitary Fibrous Tumor: Two Cases Including Doege-Potter Syndrome.Cureus · 2026Article
- Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution.Annals of surgical oncology · 2026Article
- CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS).Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- ASO Practice Guidelines Series: Multidisciplinary Management of Retroperitoneal Sarcomas.Annals of surgical oncology · 2025Review
- Gene and Cell Therapy for Sarcomas: A Review.Cancers · 2025Review
- From Data Integration to Precision Medicine: A Value-Based Healthcare Approach for Sarcoma Care.Journal of clinical medicine · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue sarcomas are a diverse and heterogeneous group of cancers of mesenchymal origin. Each histological type of soft tissue sarcoma has unique clinical particularities, which makes them challenging to diagnose and treat. Multidisciplinary management of these rare diseases is thus key for improved survival. The role of surgery has been well established, and it represents the cornerstone curative treatment for soft tissue sarcomas. To date, local recurrence is the leading cause of death in low-grade sarcomas located at critical sites, and distant metastasis in high-grade sarcomas, regardless of the site of origin. Management must be tailored to each individual histologic type. We describe the most common types of extremity, trunk, abdominal, and retroperitoneal soft tissue sarcoma along with characteristics to consider for optimized management.
Indexed as
Identifiers
39174839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.